A further funding injection brings the company one step closer to launching its hormone-free formulations to help manage hot flashes, anxiety and low testosterone levels.
Rebalance Health has successfully secured a further $7.37 million in funding following a Series C round, bringing its total raised to around $19 million.
The funding will help the company launch its hormone-free supplement range, which has been shown to help manage hot flashes, anxiety and low testosterone production.
The Colorado based Rebalance was founded by Justin Hai, co-founder of Alastin, after his wife was diagnosed with Cushing’s disease, a rare condition characterised by an individual having high cortisol levels over an extended time, which affects 10 – 15 people per million every year.
Mr Hai previously told Vator News: “The motivation for starting the brand began when I was researching ways to help my wife. I talked with cortisol experts, some are now part of the Rebalance Health’s science team, and saw how there is a disconnect in supplements. They tend to only focus on symptoms, instead of the solution and I wanted to change that.”
The solution-focused supplement line has been developed using Rebalance’s proprietary delivery technology which allows the products and their ingredients to be absorbed by the body without being broken down by stomach acid in the digestive system.
The range includes The Hot Flash System, which the company says has been shown to reduce or eliminate hot flashes and other menopausal symptoms; The Anxiety System, which is designed to lower side effects of generalised anxiety; and The Testosterone System, which aims to combat symptoms related to low testosterone production.
“Everyone’s hormones are related to cortisol and Rebalance highlights the fact that hormones need to be in the proper ratios. That’s what Rebalance is designed to do: to help balance cortisol levels throughout the day and optimise your sleep. We aren’t trying to replace hormones that are missing (since that is not a long-term solution), we are helping activate what wants to be working for you by regulating cortisol levels,” Mr Hai explained.
“When we set out to solve high cortisol we discovered in the process a natural solution of hot flashes and low testosterone. We found a way to naturally reduce anxiety while providing other benefits to the mind and body by creating a lozenge system that synchronises with your circadian rhythm.”
In studies, Rebalance found that around two weeks, women’s oestrogen levels started to increase as cortisol levels came down, while men’s testosterone started to increase as cortisol went down within a few weeks.
Mr Hai continued: “What we didn’t anticipate was the hot flashes were eliminated from women in our study as the cortisol went down and as oestrogen was rebalanced. This abstract from this study will be published later this year.”
With this additional funding injection, Rebalance Health is now one step closer to launching its range, having welcomed over 100 investors in an initiative that will also be used to increase consumer awareness.
The investors in the round were not named but Hai said: “Rebalance Health is funded by private investors that have been repeat investors in our deals. We believe in syndicating our deals and, based on our history of ventures, we have a strong following.”
Part of Rebalance’s mission is to take away some of the fear that bad actors instil in consumers for financial gain with no science and effort to show efficacy specific to their product.
“Rebalance is about real science, and a proven product supporting at scale the human population from the pandemic of sleep apnea causing havoc on our endocrine system,” added Hai.
“Our product line exists to support various symptoms from cortisol. As one example of the many symptoms we support, there are 47 million women that enter menopause annually, which lasts for a duration of 7-14 years. Success is helping as many people as possible live a happier, balanced and calm life with our natural proven solution.”
